AlphAIAlphAI — Financial news for AI agents
aol.comSEP 213 min read$ABT

Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth

Abbott Laboratories (ABT) reported higher quarterly revenue than Intuitive Surgical (ISRG) over the last eight quarters, but ISRG grew revenue at a faster pace. ABT's revenue grew 19% from Q3 2024 to Q2 2026, while ISRG's revenue grew 45%. Both companies have steady revenue trajectories. ABT reported a 14% operating margin, ISRG 34%. ABT offers a 2.5% dividend yield.

Original reporting
aol.com
Published Sep 21, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth — source image
Source · aol.com
Decision brief

The 30-second read

$ABTNeutralLow
01

Why it matters

No new data; the piece is a retrospective comparison that offers limited trading insight.

02

Market read

Primarily an informational comparison; unlikely to drive immediate trading activity.

03

What to watch

Potential impact of upcoming product launches or regulatory changes not covered in the article.

Relevance 4/10Novelty 2/10Timing: post‑quarter commentary

Background

The article provides a side‑by‑side revenue trend analysis of Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) using recent quarterly filings.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Article compares Abbott Laboratories' revenue growth and mentions its operating margin and recent licensing agreement.

Expected impact

Limited impact; price likely unchanged.

Evidence & confidence

The piece recites already‑public quarterly data without fresh disclosure.

$ISRGNeutralHigh confidence
Context

Article compares Intuitive Surgical's revenue growth and notes its operating margin and product recall handling.

Expected impact

Limited impact; price likely unchanged.

Evidence & confidence

The piece recites already‑public quarterly data without fresh disclosure.

Market effects

Sector

Highlights differing growth rates in the broader healthcare equipment sector.

Regional

U.S. healthcare stocks may see modest attention but no immediate shift.

Global

Limited; mainly U.S. investors.

Counterpoint

What could challenge this read

Despite slower growth, Abbott's larger scale and dividend may appeal to income‑focused investors.

Key entities

  • Company
    Abbott Laboratories

    U.S. healthcare conglomerate.

  • Company
    Intuitive Surgical

    Maker of robotic surgical systems.

Read at source← All news

Related articles

SEP 21
$ABTMedAI 8/10

NC reaches settlement with Abbott over contaminated baby formula that led to 2022 shortage

North Carolina settled with Abbott Laboratories for $384M over contaminated baby formula, part of a broader agreement with 39 states and the federal government. Abbott, which produces over 40% of U.S. formula, was accused of selling unsafe products and concealing test results. The recall caused a 2022 shortage. North Carolina's share is $216K, earmarked for Medicaid and nutrition programs.

wral.com2 min
SEP 21
$ABTHighAI 8/10

Abbott Laboratories To Pay $385M Over Allegations Of Tainted Infant Formula

Abbott Laboratories will pay $385M to resolve allegations of tainted infant formula. The settlement includes $348.7M to the federal government and $35.5M to state Medicaid programs. California's share is over $15M. The allegations span 2018-2022, involving production conditions that risked microorganism contamination. Abbott recalled several formula brands in 2022, leading to a nationwide shortage.

patch.com2 min
SEP 20
$ABTLowAI 8/10

Sunday Edition: Sodium

Abbott Laboratories agreed to pay $384.9M to settle a DOJ case over a 2022 infant formula outbreak. The settlement doesn't determine liability. Pending lawsuits remain. No specific company was named in an E. coli and Salmonella outbreak linked to seed supplier Everything Sprouts LLC. Italy's hepatitis A outbreak affected 130 people, possibly from bivalve mollusks. UK small businesses show good food safety practices but low awareness of food crime.

foodsafetynews.com4 min
SEP 20
$ABTLow

State settles infant formula contamination lawsuit, more Health Headlines

Colorado will receive nearly $2 million from Abbott Laboratories as part of a $348 million settlement over allegations of misrepresenting the safety of its infant formula, with additional $35.5 million to be split among states. The lawsuit claimed Abbott failed to maintain safety standards and disclose contamination test results. The funds will be returned to Colorado's Medicaid program.

gjsentinel.com2 min
SEP 19
$ABTMedAI 8/10

Abbott Laboratories Pays 384 Million In Baby Formula Safety Settlement

Abbott Laboratories (ABT) will pay $384 million to settle a lawsuit alleging it failed to maintain safety standards in its baby formula manufacturing facilities from 2018 to 2022, according to New York Attorney General Letitia James. The settlement includes $348 million to the federal government and $35 million to a coalition of states, with New York receiving $9.3 million. The lawsuit claimed Abbott's practices put products at risk of contamination and misled safety inspectors.

wpdh.com2 min